Glucose blunts GHRH-driven GH release, giving fasted dosing a basis

Why do growth hormone peptide protocols say to inject fasted?

Fasted dosing has a direct test behind it: an oral glucose load blunted the growth hormone response to a GHRH injection. Subjects took 75 g of oral glucose or plain water 30 minutes before a GHRH injection, and the GH response was measured in both healthy and hyperthyroid subjects ^[7]. The glucose load blunted the GH response relative to water, a controlled comparison on the hormone in question.

What does food do to the growth hormone pulse?

Food, especially glucose, raises insulin and shifts somatostatin tone in a way that dampens the GHRH-driven pulse. Growth hormone leaves the pituitary in pulses, not a steady drip, and two hypothalamic signals set the rhythm: GHRH pushes the pulse out, and somatostatin holds it back.

Continuous octreotide, a somatostatin mimic, was used to hold somatostatin tone artificially high in healthy men. It suppressed 24-hour mean GH by 52%, pulse amplitude by 47% and trough GH by 39%, and it cut the GH response to GHRH by 38% ^[4]. Somatostatin tone is the lever the fasted rule pulls.

Does the fasted rule apply equally to GHRP secretagogues?

GHRP-type secretagogues and GHRH-mimetic compounds differ in their sensitivity to raised somatostatin tone. The same octreotide study found that while somatostatin suppressed the GHRH response by 38%, it left the response to a GHRP-type secretagogue essentially unaffected ^[4]. That difference points to the two classes not being equally sensitive to the same food-driven somatostatin rise. A blanket rule for every compound on a protocol sheet glosses over that pharmacological difference. GHRP-2's own evidence and sermorelin's adult-use record cover the two classes separately.

Why do protocols say to inject at bedtime?

Bedtime dosing lines up with the body's own largest GH pulse: roughly 70% of daily growth hormone output in men occurs during early sleep, tied to slow-wave sleep ^[8].

A repetitive-bolus study confirmed that the nocturnal augmentation of the GH pulse persists with repeated GHRH dosing across a week, with no blunting of pituitary response by day 7 despite a large rise in IGF-I ^[5]. In children with growth hormone insufficiency, nighttime subcutaneous GHRH infusion increased pulsatile GH release compared with placebo, in a dose-dependent way ^[2]. Those children are a specific clinical population, not healthy adults timing an injection around dinner.

Does the clock matter, or does sleep?

Sleep architecture drives the pulse, not the sun going down. A study of night-shift workers found total 24-hour GH output did not differ from day workers regardless of when they slept, and the pulse pattern reorganized around whenever sleep occurred ^[6].

"Take it at bedtime" is a reasonable proxy for "take it near deep sleep." It is not a fixed clock-time rule, and someone with an irregular sleep schedule does not violate a biological law by dosing in the afternoon.

Where do the 20, 30 and 60-minute windows come from?

The 20, 30 and 60-minute pre- and post-dose windows on protocol sheets come from general insulin kinetics, not from any trial. None of the studies below tests those windows against sermorelin, ipamorelin, CJC-1295, GHRP-2/6 or tesamorelin directly, so the numbers are extrapolations. The actual evidence on ipamorelin covers what has been measured for one of those compounds.

Does dietary fat or protein blunt the growth hormone pulse?

Dietary fat and protein have not been tested as independent suppressors of the GH pulse in any of the studies below. No comparable controlled comparison exists, so the glucose finding ^[7] does not extend to them.

Why were the foundational studies run in fasted subjects?

Fasted sampling was a study-design choice. Several foundational pulsatility studies sampled blood every 10 to 20 minutes overnight in fasted, resting subjects, because that is the cleanest window for observing endogenous GH and ghrelin pulses without meal-related noise ^[1]⁠^[8].

That choice explains why "fasted" became baked into research design. It does not demonstrate that a fed state ruins a single dose's effect by some specific percentage.

Even within the fasted state, the response depends on the secretagogue. Combined GHRH plus arginine significantly stimulated ghrelin secretion in one fasted-state protocol, while GHRH alone had little effect on ghrelin ^[1].

Do these timing rules apply to every peptide?

Timing rules built on glucose suppression of the GHRH axis apply only to compounds that act on that axis. Compounds acting on tissue repair or pigmentation pathways do not act on the GHRH/somatostatin/ghrelin system, so the rule has no mechanistic reason to apply to them. Peptide cycling's evidence base covers another rule applied across unrelated compounds.

What is still unknown about peptide dosing timing?

The endpoints that would settle most protocol arguments have not been measured:

• Specific windows. No study tests the 20, 30 or 60-minute windows against sermorelin, ipamorelin, CJC-1295, GHRP-2/6 or tesamorelin.
• Fat and protein. No study tests dietary fat or protein as an independent suppressor of the GH pulse.
• A blunted pulse. No study establishes that a single blunted pulse, from eating too soon before or after a dose, has any measurable consequence. The endpoints measured are hormone concentrations and pulse characteristics, not downstream physical outcomes.
• Consistency versus precision. Chronic dosing studies show the pituitary remains responsive to repeated GHRH exposure over a week without desensitizing ^[3]⁠^[5], which suggests consistency of use matters more than precision of the clock. That inference is not a tested claim.